Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
This marks the fourth acquisition by Corona Remedies from multinational corporations
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Subscribe To Our Newsletter & Stay Updated